FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123658162> ?p ?o ?g. }

• W2123658162 abstract "The mammalian target of rapamycin (mTOR) has proven to be a valid therapeutic target in a number of human cancers, and it is a candidate for clinical trials in human breast cancer. We report on a biomarker-based translational medicine approach to assess the efficacy and mechanism of action for the mTOR inhibitor temsirolimus (CCI-779) in a mammary carcinoma OncoMouse model [polyomavirus middle T antigen (PyMT)]. The mTOR signaling pathway biomarkers were assessed using a reverse-phase protein array. Pharmacokinetics studies were conducted in both the tumor and plasma compartments. Pharmacodynamic biomarkers for compound-target engagement of tumor phospho-S6 proteins were assayed by Western blot. Temsirolimus (intravenously once a week for 2 weeks) was administered in both early and advanced stages of tumors. Biomarkers for temsirolimus effects on tumor progression were assessed by three-dimensional ultrasound imaging in combination with immunohistochemistry to assess vascular density (Texas red-dextran and CD31 immunostaining) and macrophage burden (F4/80 antigen). Tumor growth was significantly arrested in temsirolimus (25 ± 14% from 8 to 10 weeks, p < 0.05, and 26 ± 17% from 11 to 13 weeks, p < 0.01), compared with 493 ± 160 and 376 ± 50% increases, respectively, in vehicle-treated groups. Temsirolimus reduced tumor vascular density, 36 to 48 and 58 to 60%, p < 0.05, by the Texas red-dextran method or CD31-positive vessel count, respectively. Temsirolimus reduced tumor macrophage burden by 46% at 13 weeks (p < 0.05). Temsirolimus inhibited (p < 0.05) the phosphoproteins S6 pS235/236 and S6 pS240/244 up to 81 and 87%, respectively. We conclude that the multimodal biomarkers of temsirolimus efficacy and mechanism of action (phosphoproteins) strongly suggest that it might translate to therapeutic efficacy in human tumors that bear congruency to features present in the mammary carcinoma of PyMT tumors." @default.
• W2123658162 created "2016-06-24" @default.
• W2123658162 creator A5003026401 @default.
• W2123658162 creator A5010517097 @default.
• W2123658162 creator A5012502619 @default.
• W2123658162 creator A5020739585 @default.
• W2123658162 creator A5032149939 @default.
• W2123658162 creator A5062809743 @default.
• W2123658162 creator A5064894012 @default.
• W2123658162 creator A5081780524 @default.
• W2123658162 date "2011-08-11" @default.
• W2123658162 modified "2023-09-29" @default.
• W2123658162 title "Multimodal Biomarker Investigation on Efficacy and Mechanism of Action for the Mammalian Target of Rapamycin Inhibitor, Temsirolimus, in a Preclinical Mammary Carcinoma OncoMouse Model: A Translational Medicine Study in Support for Early Clinical Development" @default.
• W2123658162 cites W1500151013 @default.
• W2123658162 cites W1970002782 @default.
• W2123658162 cites W1975045667 @default.
• W2123658162 cites W1987484454 @default.
• W2123658162 cites W1987959125 @default.
• W2123658162 cites W1988609792 @default.
• W2123658162 cites W1994001783 @default.
• W2123658162 cites W1994357669 @default.
• W2123658162 cites W1996213381 @default.
• W2123658162 cites W1998762942 @default.
• W2123658162 cites W2003043566 @default.
• W2123658162 cites W2003470917 @default.
• W2123658162 cites W2008825756 @default.
• W2123658162 cites W2013647024 @default.
• W2123658162 cites W2014892762 @default.
• W2123658162 cites W2025644637 @default.
• W2123658162 cites W2033319153 @default.
• W2123658162 cites W2041394514 @default.
• W2123658162 cites W2052223356 @default.
• W2123658162 cites W2054780042 @default.
• W2123658162 cites W2086899319 @default.
• W2123658162 cites W2089258206 @default.
• W2123658162 cites W2092661658 @default.
• W2123658162 cites W2102648794 @default.
• W2123658162 cites W2104104624 @default.
• W2123658162 cites W2107296734 @default.
• W2123658162 cites W2111449140 @default.
• W2123658162 cites W2112130045 @default.
• W2123658162 cites W2115458177 @default.
• W2123658162 cites W2139042348 @default.
• W2123658162 cites W2142506125 @default.
• W2123658162 cites W2145341466 @default.
• W2123658162 cites W2147207558 @default.
• W2123658162 cites W2147394591 @default.
• W2123658162 cites W2172111870 @default.
• W2123658162 doi "https://doi.org/10.1124/jpet.111.185249" @default.
• W2123658162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21835932" @default.
• W2123658162 hasPublicationYear "2011" @default.
• W2123658162 type Work @default.
• W2123658162 sameAs 2123658162 @default.
• W2123658162 citedByCount "8" @default.
• W2123658162 countsByYear W21236581622012 @default.
• W2123658162 countsByYear W21236581622013 @default.
• W2123658162 countsByYear W21236581622014 @default.
• W2123658162 countsByYear W21236581622015 @default.
• W2123658162 countsByYear W21236581622016 @default.
• W2123658162 countsByYear W21236581622019 @default.
• W2123658162 crossrefType "journal-article" @default.
• W2123658162 hasAuthorship W2123658162A5003026401 @default.
• W2123658162 hasAuthorship W2123658162A5010517097 @default.
• W2123658162 hasAuthorship W2123658162A5012502619 @default.
• W2123658162 hasAuthorship W2123658162A5020739585 @default.
• W2123658162 hasAuthorship W2123658162A5032149939 @default.
• W2123658162 hasAuthorship W2123658162A5062809743 @default.
• W2123658162 hasAuthorship W2123658162A5064894012 @default.
• W2123658162 hasAuthorship W2123658162A5081780524 @default.
• W2123658162 hasConcept C121608353 @default.
• W2123658162 hasConcept C126322002 @default.
• W2123658162 hasConcept C183713625 @default.
• W2123658162 hasConcept C190283241 @default.
• W2123658162 hasConcept C2776820818 @default.
• W2123658162 hasConcept C2778939058 @default.
• W2123658162 hasConcept C2780394083 @default.
• W2123658162 hasConcept C2781197716 @default.
• W2123658162 hasConcept C502942594 @default.
• W2123658162 hasConcept C55493867 @default.
• W2123658162 hasConcept C71924100 @default.
• W2123658162 hasConcept C86554907 @default.
• W2123658162 hasConcept C86803240 @default.
• W2123658162 hasConcept C98274493 @default.
• W2123658162 hasConceptScore W2123658162C121608353 @default.
• W2123658162 hasConceptScore W2123658162C126322002 @default.
• W2123658162 hasConceptScore W2123658162C183713625 @default.
• W2123658162 hasConceptScore W2123658162C190283241 @default.
• W2123658162 hasConceptScore W2123658162C2776820818 @default.
• W2123658162 hasConceptScore W2123658162C2778939058 @default.
• W2123658162 hasConceptScore W2123658162C2780394083 @default.
• W2123658162 hasConceptScore W2123658162C2781197716 @default.
• W2123658162 hasConceptScore W2123658162C502942594 @default.
• W2123658162 hasConceptScore W2123658162C55493867 @default.
• W2123658162 hasConceptScore W2123658162C71924100 @default.
• W2123658162 hasConceptScore W2123658162C86554907 @default.
• W2123658162 hasConceptScore W2123658162C86803240 @default.
• W2123658162 hasConceptScore W2123658162C98274493 @default.
• W2123658162 hasLocation W21236581621 @default.
• W2123658162 hasLocation W21236581622 @default.
• W2123658162 hasOpenAccess W2123658162 @default.

• next